1. Introduction {#sec1-jcm-08-00917}
===============

Adipose tissue stem cells (ASCs) are considered as a type of mesenchymal stem cell (MSC) in stromal vascular fractions (SVF) which are isolated from fat tissues enzymatically. Thus, ASCs express the typical surface markers of stem cells and have potentials to differentiate into multiple lineages as MSCs. However, fluorescence-activated cell sorting (FACS) shows the different expressed surface marker profile between MSCs and ASCs. In fact, ASCs are a heterogeneous population consisting of adipose tissue-derived stromal cells and MSCs. In SVFs from adipose tissue and bone marrow, Y. Jang et al. identified six major cell types; while adipose tissue contains a significant number of MSCs and ASCs together with a much lower number of leukocyte than those in the bone marrow. In-vitro, ASCs can be differentiated into osteoblasts, chondroblasts, adipocytes, myocytes, and cardiomyocytes in suitable conditions \[[@B1-jcm-08-00917],[@B2-jcm-08-00917],[@B3-jcm-08-00917]\]. Adipose tissue consists of 100--500 folds higher number of stem cells compared to bone marrow, which makes ASCs an attractive source for human usage. ASCs show therapeutic impacts on angiogenesis, wound healing, and the immune regulatory system. Since the first isolation and classification of ASCs in 2001, the studies about ASCs human trials have been increasing year by year starting from 2007 and reaching its peak in 2015 with up to 187 clinical trials using adipose stem cells. There are six trials registered in [clinicaltrial.gov](clinicaltrial.gov) in the first quarter of 2019 ([Figure 1](#jcm-08-00917-f001){ref-type="fig"}). Most of the studies have been conducted in East Asia, Europe, North America and United States ([Table 1](#jcm-08-00917-t001){ref-type="table"}) in phase I and phase II ([Figure 2](#jcm-08-00917-f002){ref-type="fig"}) for treatment of skeletal diseases, gastrointestinal diseases, skin diseases, nervous disorders, autoimmune diseases, diabetes mellitus, lung and heart diseases. In general, ASCs can be isolated from the collected adipose tissues in patients and directly injected into the wounds, bloodstream, or encapsulated in biomaterials and implanted in the wounds. Many investigations showed ASCs can increase the healing rate and decrease healing time both in-vitro and in-vivo \[[@B4-jcm-08-00917],[@B5-jcm-08-00917],[@B6-jcm-08-00917]\]. ASCs can directly differentiate into specific cell lineages such as keratinocytes, fibroblast-like cells, and endothelial cells, together with the release of growth factors and cytokines, all that promote angiogenesis, development, migration of fibroblasts, and production of fibronectin and collagen. These results are consistent in 14 clinical trials data (in [clinicaltrial.gov](clinicaltrial.gov) datasheet). They showed improvement of healing in chronic ulcers and in the reduction of pain. However, further studies are needed to accurate the role of ASCs in cancer therapy \[[@B7-jcm-08-00917]\]. Besides, ASCs are also used in many types of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes mellitus \[[@B8-jcm-08-00917]\]. ASCs contribute to maintaining the balance of the immune system by regulation of T-cell as well as IL-10 secretion and activity. The ASCs encapsulated in biomaterials used for plastic surgeries are considered prevalent in East Asian countries. This system promotes wound healing process and reduces the possibility of scar formation or old scar re-emergence upon the body surface. However, is difficult to control the dosage and safety of ASCs in plastic surgery. Residue collagenase can be harmful to skin or tissue regeneration. It is necessary to determine the effective dose, route, and safety for each indication associated with skin surface or skin conditions in further studies \[[@B9-jcm-08-00917]\].

Despite being discovered only two decades ago, stem cell therapy using ASCs has been developed as regenerative medicine in a series of serious diseases \[[@B13-jcm-08-00917],[@B14-jcm-08-00917],[@B15-jcm-08-00917]\]. Besides, ASCs therapy has been evaluated for advantages and disadvantages in both research and clinical applications. Most authors agreed that ASCs have strong multipotent potential differentiation---easy to harvest and isolate; large and various origins; varying in application method; and high anti-inflammation, immune regulating and angiogenic effects compared to other stem cells and compared to other clinical therapies \[[@B8-jcm-08-00917],[@B16-jcm-08-00917]\]. Most of the investigations considered ASCs transplantation as a safe technique, whereas using SVFs is safer than ASCs \[[@B17-jcm-08-00917],[@B18-jcm-08-00917]\]. Additionally, the side effects of stem cell therapy are regularly originated from the expansion steps which can cause DNA damage linked to senescence and transformation in long-term cultivation \[[@B17-jcm-08-00917],[@B19-jcm-08-00917]\]. ASCs can be isolated from patient adipose tissue in the laboratory and injected back into those patients directly. The quality of ASCs depends on the purifying method and storage condition \[[@B19-jcm-08-00917],[@B20-jcm-08-00917]\]. The cells must be carefully evaluated based on stability, toxicity, contaminations, and senescence in culture \[[@B20-jcm-08-00917]\]. A prospective study in 1524 patients using SVFs was performed in United States from 2011 to 2016. The data showed the safety and improvement outcomes by SVFs \[[@B21-jcm-08-00917]\]. Moreover, preclinical trials have been conducted to evaluate the safety of using human ASCs on animals. In rabbit, there were no systemic side effects by ASCs transplantation to treat osteoarthritis \[[@B22-jcm-08-00917]\]. According to the update data in [clinicaltrial.gov](clinicaltrial.gov) until April 2019, there are, in total, 103 trials using ASCs or SVF in early phase I and phase I. The completed trials have shown the safety and positive results of ASC therapies in human \[[@B23-jcm-08-00917],[@B24-jcm-08-00917]\]. Recently, a safety test using adipose tissue MSCs has been done to treat cerebral palsy in a pediatric patient. The patient significantly improved in overall health over a 12-month trial \[[@B24-jcm-08-00917]\].

As with other stem cell therapy, some ASC trials are in terminated or suspended status. According to [clinicaltrial.gov](clinicaltrial.gov), there are 7 terminated trials---NCT01623453, NCT01314092, NCT01011686 (South Korea), NCT02326935 (Cayman Island), NCT02741362 (United State), NCT01378390 (Europe), and NCT01532076 (Switzerland). The failure may be related to insufficient financial support \[[@B25-jcm-08-00917]\]. The effects of ASC therapy vary on the type of cell and transplantation route. Thus, it is necessary to further evaluate large-scale ASC transplantation studies in animal and human trials.

2. Characteristics of ASCs {#sec2-jcm-08-00917}
==========================

Adipose tissue is regarded as an abundant source of adult stem cells and easy to access in the human body. White adipose tissues (WAT), the main storage of energy, contain huge numbers of ASCs compared to brown adipose tissues (BAT), Besides, ASCs isolated from WAT and BAT showed unlike characteristics in the differentiation ability. In clinical applications, ASCs have mostly been isolated from WAT in subcutaneous depots. It is important to develop and optimize ASCs-related technologies such as the harvesting, isolation, and storage of these cells, which are suitable for clinical application. Generally, ASCs can be obtained in SVFs after removing no-adhesion-plastic cells after 24 h culture. The cell population will be classified based on specific markers on cell surfaces by flow cytometry. Quality and quantity of ASCs thus depend on the isolation methods. Interestingly, most studies showed ASCs are heterogeneous population characterized by groups of surface markers, containing MSCs, adipose stromal cells, endothelial progenitors, pericytes and hematopoietic cells. Compared to bone marrow, the number of SVF cells, or even MSCs and ASCs in adipose tissue are 4--6 folds higher, 4.28% for MSCs and 32% for adipose stromal cells respectively in SVFs \[[@B16-jcm-08-00917]\]. The selected markers for classification of ASCs population may vary by investigations \[[@B26-jcm-08-00917],[@B27-jcm-08-00917]\]. ASCs can express MSC marker CD90 and other markers such as CD34, CD73, and CD105 \[[@B28-jcm-08-00917]\], which is consistent with minimal criteria for defining MSCs by the International Society for Cellular Therapy (ISCT) and the International Fat Applied Technology Society (IFATS) \[[@B29-jcm-08-00917],[@B30-jcm-08-00917]\]. According to IFATS, original ASCs can be defined by positive marker CD34 and negative markers CD45, CD235a and CD31; while cultured ASCs expressed CD73, CD90, CD105, CD44 and were negative with CD45 and CD31. The authors pointed out that CD36+/CD106− markers can be used for distinction with bone marrow stem cells \[[@B29-jcm-08-00917]\]. The morphology and gene expression profile of ASCs are similar to other MSCs derived from bone marrow and umbilical cord. Wolfgang Wagner et al. showed 25 up-regulated genes which overlapped between MSCs from different sources and isolation methods \[[@B31-jcm-08-00917]\]. This suggests using 25 defined genes to classify stem cells among others cell population together with cell surface markers by screening method. In the expansion culture, ASCs can achieve the maximum proliferation in 10% Fetal Bovine Serum (FBS) medium or even a mixture of low FBS and separate growth factor medium \[[@B32-jcm-08-00917]\]. ASCs showed similar morphology and differentiation characteristics to MSCs from bone marrow \[[@B33-jcm-08-00917]\]. ASCs can be differentiated into adipocytes, osteoblasts, chondroblasts, hepatocytes, and neuron cells in different conditions \[[@B2-jcm-08-00917],[@B3-jcm-08-00917],[@B26-jcm-08-00917],[@B33-jcm-08-00917],[@B34-jcm-08-00917],[@B35-jcm-08-00917],[@B36-jcm-08-00917],[@B37-jcm-08-00917],[@B38-jcm-08-00917]\]. In addition, ASCs is also going to be senescence; however, this characteristic is varied by patients \[[@B33-jcm-08-00917]\], and it may be a challenge to ASCs researches.

3. Processes in Isolation of ASCs {#sec3-jcm-08-00917}
=================================

The isolation processes of ASCs have been developed and optimized for 20 years, which is more suitable for therapeutic application. Zuk et al. first isolated ASCs in 2001 by using collagenase type II to digest adipose tissues and washing with NH4Cl several times which was summarized in [Figure 3](#jcm-08-00917-f003){ref-type="fig"} \[[@B39-jcm-08-00917]\]. This enzymatic isolation process is most useful and effective for clinical use. In 2017, Raposio et al. developed the standard protocol for isolation of ASCs that showed the maximum in the number of stem cells obtained from liposuction (9.06 × 10^5^ cells per 100mL of adipose tissue) with 99% cell vitality \[[@B40-jcm-08-00917]\]. This process was performed in a closed circulation with minimum contamination and minimal time consumption, that guarantees safety and efficiency of stem cells for clinical uses. Besides the enzymatic method, adipose tissue can be digested by the non-enzymatic method \[[@B27-jcm-08-00917],[@B41-jcm-08-00917]\]. The non-enzymatic method is proposed as an economical method and effective for fat grafting in skin diseases \[[@B41-jcm-08-00917]\]. However, in term of the number of collected ASCs, the enzymatic isolation method is more effective than the non-enzymatic process, 25.9% and 5%, respectively \[[@B27-jcm-08-00917]\].

ASCs are isolated from SVFs, a group of many cell types. SVF cells have different characteristics as well as surface markers. Classification ASCs may be based on specific markers, which were screened by flow cytometry. Moreover, Zuk and his groups demonstrated that it is impossible to separate SVFs population by single marker \[[@B39-jcm-08-00917]\]. The standard specific surface markers of ASCs are still developing. Researchers have been used different surface markers to classify SVFs. However, they totally agree that ASCs express MSCs markers such as CD90 \[[@B16-jcm-08-00917],[@B27-jcm-08-00917],[@B42-jcm-08-00917],[@B43-jcm-08-00917]\]. ASCs positively express CD34^+^, CD90^+^, and negatively express CD31^−^, CD34^+/−^, CD45^−^, CD105^−^, and CD146^−^ markers \[[@B33-jcm-08-00917]\], while other authors investigated different positively expressed markers such as CD73^+^ in ASCs \[[@B27-jcm-08-00917]\]. ASCs also share the same surface markers to endothelial progenitors and pericytes \[[@B33-jcm-08-00917]\]. Pham et al. also reported the list of markers expressed by ASCs, which are varied by studies \[[@B26-jcm-08-00917]\]. Expression of those markers is dependent on isolation method, time incubation, and culture condition, which are associated with a different marker profile in primary and cultured cells \[[@B44-jcm-08-00917]\]. However, the isolation method can be done by the closed and automatic system which reduces clinical intervention and prevents any contamination \[[@B45-jcm-08-00917],[@B46-jcm-08-00917]\]. In 2013, Joel A. Aronowitz and Joshua D.I. Ellenhorn evaluated 4 semi-closed isolation systems. The authors reported the Celution System with automatic procedure can obtain the highest number of viable cells, ASCs with the lowest number of residual enzymes compared to manual systems as Multi Station, Lipokit, and Cha-Station \[[@B46-jcm-08-00917]\]. In 2017, Jonathan Rodriguez et al. continued to compare the quality, morphology, proliferation, and differentiation of obtained ASCs from 3 closed devices (GID-SVF1, Stem.Pras, and Puregraft). The authors emphasized the equivalent of ASCs quality among 3 systems, the possibility of practical application as well as GMP facilities \[[@B46-jcm-08-00917]\]. The current ASCs or SVFs isolation systems from adipose tissues are summarized in the [Table 2](#jcm-08-00917-t002){ref-type="table"}. Besides, the closed and sterilized kits are also available for research use, such as SynGenX-1000, SynGenX-2000, Sepax-2, and StromaCell.

4. Processes in the Culture of ASCs {#sec4-jcm-08-00917}
===================================

It is clear that both freshly isolated SVF cells and cultured ASCs are currently used in clinical applications because of their premium characteristics in regulatory requirements, facilities, cost, dose, and time consumption \[[@B47-jcm-08-00917],[@B48-jcm-08-00917],[@B49-jcm-08-00917]\]. Expansion culture of ASCs amplifies and produces a homogeneous cell population that eliminates the variability of the donor factors. However, this process generates more chances for contamination as well as losing stem cell characteristics during long-term culture \[[@B47-jcm-08-00917],[@B50-jcm-08-00917],[@B51-jcm-08-00917]\]. Thus, the culture of ASCs should be carefully evaluated for quality and safety prior to clinical use. The expansion culture of ASCs should be satisfied with the good manufacturing practice (GMP) guidelines which are reported and validated by Hamid-Reza Aghayan et al. \[[@B52-jcm-08-00917]\]. The protocol covers the step-by-step method of the collection, isolation, cultivation, and storage of ASCs. Hamid-Reza Aghayan et al. also mentioned the importance of in-process control (IPC) and quality control of ASCs product. It is useful to standardize the manufacturing process of ASCs and minimize the risks regarding the quality and safety of the product for clinical uses. Phuc Van Pham and his group established some additional guidelines for ASCs manufacturing \[[@B53-jcm-08-00917]\]. By this, the cultured ASCs must be checked for specific surface markers and cell viability, which are related to their phenotypes, self-renewable, and differentiation ability. The authors also demonstrated that hypoxic growth environments are one of the criteria in GMP guideline, which is consistent with the fact that low oxygen can promote growth rates and maintain stem cell functions \[[@B50-jcm-08-00917]\]. Recently, Francesco et al. validated and improved the GMP grade protocol for ASCs isolation, expansion, and storage from SVFs freezing and thawing \[[@B54-jcm-08-00917]\]. DMEM/F-12, α-MEM or DMEM/low glucose media supplement with FBS, growth factors, or cytokines are generally used in traditional ASCs culture \[[@B49-jcm-08-00917],[@B53-jcm-08-00917]\]. Since serum supplement in culture medium can cause allergies related to xenogeneic proteins to patients \[[@B17-jcm-08-00917],[@B53-jcm-08-00917]\], the xeno-free cultures have been developed with the addition of human serum, plasma platelet lysate, or platelet-rich plasma instead of FBS or fetal calf serum (FCS). In early 2018, the large-scale preparation of ASCs using platelet lysate in a closed and automatic system has been developed \[[@B55-jcm-08-00917]\]. The investigation showed 5% human platelet lysate supplied in the system can significantly increase the proliferation rate whereas maintaining the genetic feature of ASCs compared to 10% FBS supplement. This finding can be helpful to prepare ready-to-use allogeneic ASCs for clinical application. Besides, human serum enhances the ASCs proliferation without any differences in morphology or immunostaining profile compared to traditional culture with FBS \[[@B53-jcm-08-00917]\]. Blood-derived products consisted of many growth factors compared to FBS or FCS can be useful to maintain the high proliferation rate, stem cell properties, and differentiation characteristics of ASCs in long-term cultivation \[[@B53-jcm-08-00917],[@B56-jcm-08-00917]\]. Moreover, the combination of platelet lysate and human plasma which are isolated from expired blood can reduce senescence of ASCs during cultivation \[[@B56-jcm-08-00917]\]. Besides, platelet-rich plasma added medium can stimulate the differentiation of ASCs into chondroblasts \[[@B57-jcm-08-00917]\]. Thus, recently, the serum-free medium has been developed commercially \[[@B17-jcm-08-00917]\]. STK2 medium is a chemically defined medium, which obtains a higher proliferation rate, induces stem cell surface markers as well as reduces cell senescence compared to FBS \[[@B58-jcm-08-00917]\]. The free serum and free xenogeneic-protein medium still stimulate the proliferation of ASCs with the expression of entirely stem cell morphology, surface markers, as well as differentiation ability \[[@B59-jcm-08-00917]\]. On the other hand, a research group succeeded in the scale-up of ASCs production (35L scale) in low-serum conditions \[[@B60-jcm-08-00917]\]. However, there is lack of safety evaluation and the serum-free mediums are mainly applied for research tests, not for clinical trials.

Currently, the instruments using in ASCs production are available in the market with a variety of scales from 0.5 L to 200 L of materials. Small and pilot scale systems can be suitable for autologous ASCs, whereas the large-scale systems for allogeneic ASCs manufacturing. The expansion systems are dynamic bioreactors operated with microcarriers. Dufey et al. and Lipsitz et al. succeeded in producing MSCs preparation which satisfied GMP requirements \[[@B61-jcm-08-00917],[@B62-jcm-08-00917]\]. Lawson et al. co-cultured ASCs and MSCs in the 50 L scale devices and reached the highest proliferation rate \[[@B63-jcm-08-00917]\]. Interestingly, different microcarriers and coating materials can cause changes in the cellular phenotype and gene expression profile. Therefore, it is necessary to develop and validate GMP-grade microcarriers in the system \[[@B64-jcm-08-00917]\].

In conclusion, developed medium with optimal components together with the automatic and closed instruments are useful for expansion of ASCs used in clinical transplantation. Xeno-free medium or xeno-free/serum-free medium is commercial that is the advance of ASCs culture.

5. Processes in the Differentiation of ASCs {#sec5-jcm-08-00917}
===========================================

Adipose-derived stem cells are widely accepted the differentiation capability into the multilineage cells, including adipocyte, osteocyte, chondrocyte, neuron, and other cell types \[[@B6-jcm-08-00917]\]. The cell-surface markers also show the differentiation potency of ASCs. Positive marker CD146 ASCs are more favorable to differentiate into adipocytes than negative CD146 cells \[[@B65-jcm-08-00917]\]. In addition, the differentiation condition generally drives the differentiation capability of ASCs. For instance, supplemented IBMX and insulin promote ASCs into the adipogenic lineage, while β-glycerol phosphate, vitamin, and amino acid stimulate to form osteogenic lineage completely \[[@B6-jcm-08-00917],[@B26-jcm-08-00917]\]. Insulin-like growth factor I is reported as an inducer of ASCs differentiation into hepatocytes \[[@B66-jcm-08-00917]\]. The mechanism of ASCs differentiation has been investigated. Osteogenic differentiation is reported to be link to several pathways which consists of bone morphogenetic proteins, Wnt/β-catenin, fibroblast growth factor, PKA, and ERK1/2 pathways \[[@B67-jcm-08-00917],[@B68-jcm-08-00917]\]. Zinc sulfate regulating bone formation can promote osteogenic differentiation of ASCs in rat \[[@B69-jcm-08-00917]\]. Neural differentiation requires the induction of βFGF and forskolin into several cell types \[[@B70-jcm-08-00917],[@B71-jcm-08-00917]\]. Sujeong Jang et al. investigated that neural induction is associated with Wnt5a/JNK pathway, and not Wnt/β-catenin pathway \[[@B70-jcm-08-00917]\]. In-vivo, after implantation, most ASCs die because of the stressful environment which is related to more complicated mechanism than in-vitro studies \[[@B11-jcm-08-00917]\]. The scaffolds usually used in in-vivo studies supported the proliferation and differentiation of implanted cells via their chemical compositions and physical properties \[[@B69-jcm-08-00917]\]. Collagen can be used to efficiently support the differentiation of ASCs into various lineages than alginate. Both silica nanoparticles, hyaluronic acid induce ASCs proliferation in the implanted site, while other synthetic polymers can stimulate ASCs immobilization, development and differentiation after transplantation. Different scaffolds and tissue engineering methods can be applied to suitable implantation purposes. PDM combined XLHA scaffolds usually apply in the adipogenic differentiation; PLA-PPᵧ scaffolds use for osteogenic differentiation and HA scaffolds for chondrogenic differentiation \[[@B69-jcm-08-00917]\]. All those factors have been developed and optimized to be appropriate for applying ASCs for therapeutic purposes.

6. Processes in the Storage of ASCs {#sec6-jcm-08-00917}
===================================

ASCs can be used in clinical as regenerative medicine. The storage condition is important to ensure the quality of ASCs preparation which can affect the outcome of therapy. The long-term, as well as short-term storage conditions of ASCs, have been investigated \[[@B72-jcm-08-00917],[@B73-jcm-08-00917],[@B74-jcm-08-00917]\]. The media and temperature were optimized for enhancement of ASCs viability before isolation and application \[[@B72-jcm-08-00917]\]. According to Wu et al. results, ASCs decreased their proliferation by time preservation. ASCs preparation should be stored in the supplement of 10% human serum or platelet-rich plasma in 0.9% saline solution at 4 °C and used in the first 2 h, no longer than 4 h. This result is consistent with the investigation of Nofianti et al. in 2018 \[[@B73-jcm-08-00917]\]. Physiologic saline showed higher efficiency in cell viability of ASCs compared to DMEM medium. For long-term storage, ASCs can be stored at −80 °C or liquid nitrogen up to 6 months. In those conditions, ASCs can maintain the proliferation and differentiation characteristics in culture. However, ASCs membrane may break in case of rapid freezing. The cell viability of 194 cryopreserved ASCs of different ages in 5 years of experiment were evaluated. In that, there is no correlation between the recovery and volume of collected tissue, time of preservation, and patient age \[[@B75-jcm-08-00917]\]. Moreover, in the recent study, 10-year-old ASCs have been evaluated the viability, cell morphology, and cell-surface markers compared to fresh ASCs and short-term ASCs \[[@B74-jcm-08-00917]\]. The cell viability is similar in long-term and short-term stored ASCs, 78% and 79%, respectively. However, long-term storage can affect the differentiation potential. The results showed the highest osteogenic genes expressed in short-term ASCs compared to a fresh group, while lost expression in long-term groups. Adipogenic genes are not affected by time preservation. Those results suggest using storage banks of harvested adipose tissue and thawing the estimated amount of tissue to the isolation of ASCs together with an evaluation of the quality of ASCs before implantation into patients. Besides, SVFs aliquots can be stored as the source of ASCs. SVFs should be frozen at the appropriate cell number in the serum supplemented 5% DMSO \[[@B54-jcm-08-00917]\].

7. Processes in the Clinical Application of ASCs {#sec7-jcm-08-00917}
================================================

Human adipose-derived stem cells are safe to apply to the treatment of various diseases for years \[[@B76-jcm-08-00917]\]. ASCs can be used in regenerative medicine and immunomodulators. ASCs has potential in differentiation into multiple cell lineages, which is useful for regenerative uses. ASCs have been applied in the treatment of cardiac-related diseases and tissue engineering. ASCs therapy enhances myocardial tissue regeneration and improves their functions \[[@B77-jcm-08-00917],[@B78-jcm-08-00917],[@B79-jcm-08-00917]\]. Treatment of ASCs therapy in 4 weeks in pid is a safe and effective method,) resulting in the improvement of left ventricular ejection fraction and reduction of scar volume in the ventricular wall \[[@B79-jcm-08-00917]\]. The StemBell technique divers ASCs to infarcted injuries, which significantly improved cardiac function compared to ASCs treatment only in rat \[[@B80-jcm-08-00917]\]. In addition, ASCs are also seeded in biomaterials as a scaffold and implanted in the soft tissues. ASCs can reduce scar formation and promote the healing process in cutaneous wounds \[[@B81-jcm-08-00917]\]. Besides, electrical stimulation of viability and differentiation of ASCs in scaffolds supports the treatment of bone defect and regeneration of smooth muscle tissue \[[@B82-jcm-08-00917],[@B83-jcm-08-00917]\].

ASCs can regulate the immune systems by anti-inflammatory potential \[[@B84-jcm-08-00917]\]. ASCs treatment is effective for multiple sclerosis, rheumatoid arthritis, and diabetes mellitus \[[@B8-jcm-08-00917]\]. Several randomized controlled trials reported the positive results of using ASCs injections in knee and hip osteoarthritis patients with no side effects \[[@B85-jcm-08-00917],[@B86-jcm-08-00917],[@B87-jcm-08-00917],[@B88-jcm-08-00917]\]. Isolated ASCs have been implanted or injected to osteoarthritis patients. The studies of ASCs application are more focus on the treatment of knee osteoarthritis. Kim et al. first assessed the benefits of ASCs implantation and injection in patients with knee osteoarthritis in 2015 \[[@B89-jcm-08-00917],[@B90-jcm-08-00917]\]. Both investigations showed significant pain relief and the improvement of cartilage lesions in MRI images; however, ASCs implantation showed higher improvement index value than ASCs injection group after a 1-year follow-up trial \[[@B90-jcm-08-00917]\]. The efficiency of ASCs injections in osteoarthritis did not associate with the dose of treatment. Even a low number of ASCs can greatly improve the symptoms of the disease in the knee \[[@B91-jcm-08-00917]\]. Recently, other trials have continued to be conduct on humans to determine the efficiency and safety of ASCs in osteoarthritis. Jones et al. reported the guideline to evaluate the treatment of ASCs in osteoarthritis, consisting of recruitment, ASCs preparation, and injection, analysis the results, and follow-up \[[@B54-jcm-08-00917]\]. Last year, a 3-year follow up study also confirmed the potential benefits and safety of using ASCs as regenerative medicine in the treatment of osteoarthritis \[[@B92-jcm-08-00917]\]. Supported to that, two different groups in Korea and Italy reported similar improvement results in pain and MRI image and other improvement index factors in the participants \[[@B87-jcm-08-00917],[@B88-jcm-08-00917]\]. In the trials, Lee et al. used cultured ASCs injection, while Roato et al. used the uncultured ASCs to treat the knee of patients. Thus, it is clear that the efficiency of ASCs is not dependent on the dose and form of cells.

Additionally, using ASCs has shown promising results on the treatment of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), intervertebral disc, amyotrophic lateral sclerosis (ALS), multiple system atrophy \[[@B93-jcm-08-00917]\], Parkinson and traumatic brain injury (TBI) \[[@B90-jcm-08-00917],[@B91-jcm-08-00917],[@B92-jcm-08-00917],[@B93-jcm-08-00917],[@B94-jcm-08-00917]\]. However, the efficiency of ASCs therapy in those neural related diseases is still being investigated. Most investigations were performed in mouse or rat model and were limited in size and selection criteria participants, dosage, and treatment method of ASCs \[[@B90-jcm-08-00917],[@B91-jcm-08-00917],[@B92-jcm-08-00917],[@B94-jcm-08-00917],[@B95-jcm-08-00917],[@B96-jcm-08-00917]\]. Intravenous injection of expanded ASCs ensured high safety rates, better viability and motor activity in ALS mouse \[[@B97-jcm-08-00917],[@B98-jcm-08-00917]\]. In Parkinson disease mouse model, transplanted ASCs recovered the mitochondrial functions, that showed the potential therapeutic of ASCs in the treatment of Parkinson disease \[[@B94-jcm-08-00917]\]. Co-treatment with butylidenephthalide, an extract from a traditional Chinese plant, ASCs therapy also showed the improvement of motor abilities in the experiential model \[[@B99-jcm-08-00917]\]. Currently, in a human trial, the safety test of those ASCs applications has been investigating. The intrathecal treatment of ASCs was safe in the single and double dose in 27 patients with ALS \[[@B93-jcm-08-00917]\]. Two phase I trials of ASCs treatment by injection was also reported in [clinicaltrials.gov](clinicaltrials.gov) with positive results. However, there are only two trials of ASCs implantation in Parkinson patients from 2014, but they have not yet recruited participants. There is still need for more studies to evaluate the efficiency of ASCs in those neural related diseases. For five years recently, most ASCs therapy has been studied in animal \[[@B100-jcm-08-00917]\]. In human, ASCs showed the ability to promote cell proliferation and cell viability of nucleus pulposus cells in the intervertebral disc \[[@B101-jcm-08-00917],[@B102-jcm-08-00917]\]. SVF, non-insolated ASCs from adipose tissue, can also improve the outcome in degenerative disc disease with no adverse effects \[[@B103-jcm-08-00917]\]. Autologous ASCs transplantation also recovered the slightly neural function of the spinal cord \[[@B104-jcm-08-00917]\]. ASCs transplantation enhanced endogenous neurogenesis and neural functions in AD mice model \[[@B84-jcm-08-00917]\]. A case report in human also showed the positive effects of autologous ASCs administration in moderate AD patients \[[@B105-jcm-08-00917]\]. There are 2 clinical trials which are using autologous ASCs in the treatment of AD (NCT02899091 and NCT029122169). Interestingly, most tests or trials are conducted with non-expanded ASCs. In fact, the immune-regulatory potential and expressed surface markers in ASCs are depended on the culture conditions, expansion time, and supplements which are associated with adverse effects in AD treatment \[[@B106-jcm-08-00917],[@B107-jcm-08-00917]\].

Besides, ASCs therapy is also intended in the treatment of sport injuries. Stem cells have been researched the benefits in the recovery function of anterior cruciate ligament \[[@B108-jcm-08-00917],[@B109-jcm-08-00917]\], tendon, and elbow injuries \[[@B110-jcm-08-00917],[@B111-jcm-08-00917]\]. Even then, the use of stem cell on sports injuries is still controversial \[[@B112-jcm-08-00917]\]. There is not enough evidence for the safety and efficiency of adipose stem cells therapy in sport.

In conclusion, even though ASCs have been isolated and researched for years, ASCs application is more and more focused as a source of adult stem cells in various diseases. Preclinical and clinical studies of ASCs application were summarized on [Table 3](#jcm-08-00917-t003){ref-type="table"}. However, the in-vitro experiments or human trials are limited, thus it is necessary to conduct new studies which continue to support the use of ASCs therapy in therapeutic treatment.

8. Conclusions {#sec8-jcm-08-00917}
==============

Human adipose stem cells have been researched as regenerative medicine in various diseases with promising results. According to the trials reported in [clinicaltrials.gov](clinicaltrials.gov), the number of trials of ASCs use have increased over the years. With the abundant amount in adipose tissue, ASCs is the most important source of stem cell in adults. Processing of ASCs preparations which consist of harvest, isolation, expansion, and storage have been optimized and standardized to ensure the safety and quality of ASCs for therapeutic use. Additionally, ASCs contained in SVFs can be used directly without an isolation step. In general, ASCs preparation is going to be injected or transplanted in the injury site by using scaffolds. The characteristics of scaffolds might support the adhesion, survival, and proliferation of ASCs, thus contribute to the efficiency of ASCs therapy in use. Currently, ASCs therapy has been applied to the treatment of osteoarthritis, neural, and sporty injuries. However, most investigations have been done in animal models, others in human with limited size sample and condition treatment. Therefore, it is necessary to evaluate the safety and benefits of ASCs therapy in larger participant groups and various conditions of treatment before use.

9. Future Directions {#sec9-jcm-08-00917}
====================

Researches on ASCs are about to provide more evidence for the safety and efficiency of using ASCs in clinic application instead of bone marrow stem cells. Processes of ASCs preparation have been refined to greatly contribute to the quality and quantity of ASCs prior to injection or transplantation. Modification of the scaffold components and characteristics drives ASCs location, proliferation, and differentiation into a specific cell line. However, the migration and differentiation of ASCs in-vivo is mostly still uncontrolled. The number of human trials is limited in phase I and phase II; and lacks phase III and IV trials. For the approval of ASCs in clinical use, the further challenge of ASCs can be the standardization of ASCs preparation from different patients and location, the specific healing mechanism of ASCs, effective dose, dose intervals, and appropriate delivery method to load or apply ASCs into patients. That requires the protocols for ASCs processes systematically under quality control. Phase III and phase IV of ASCs in the clinic must be approached with a larger size of participants. Moreover, the combination of ASCs therapy and other methods should be investigated, that can contribute to the promising outcome in both in vitro and in vivo experiments.
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###### 

Phase of adipose stem cell trials from 2007 to 2019 \[[@B12-jcm-08-00917]\]

  Phase                Trials
  -------------------- --------
  **Early Phase I**    6
  **Phase I**          97
  **Phase I, II**      125
  **Phase III**        7
  **Phase IV**         2
  **Not applicable**   34
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###### 

List of current systems for adipose stem cells isolation.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Device              Open/Semi-Closed/Closed   Automatic/Semi-Automatic/Manual   Capacity       Collagenenase Provided (yes/no)   Time (min)     Original Country
  ------------------- ------------------------- --------------------------------- -------------- --------------------------------- -------------- ---------------------------------------------
  Celution            Semi-closed               Automatic                         300 g          Yes                               90             Cytori Therapeutics, Inc.\
                                                                                                                                                  San Diego, CA, USA

  Multi Station       Open                      Manual                            150 g          No                                110            PNC International Co., Ltd.\
                                                                                                                                                  Gyeonggi-do, Korea

  Lipokit with 416D   Semi-closed               Manual                            100 g          No                                110            Medi-Khan\
                                                                                                                                                  Seoul, Korea

  Cha-Station         Semi-closed               Semi-automatic                    200 g          No                                90             PNC International Co., Ltd.\
                                                                                                                                                  Gyeonggi-do, Korea

  GID-SVF1 & SVF2     Closed                    Manual                            300 g          SVF1 (No)\                        90             GID Group, Inc.\
                                                                                                 SVF2 (Yes)                                       Louisville, Colorado

  Stem.pras           Closed                    Manual                            200 g          No                                110            Proteal\
                                                                                                                                                  Spain\
                                                                                                                                                  Mexico

  Puregraft 250       Semi-closed               Manual                            250 g          No                                100            Eurosilicone\
                                                                                                                                                  Zone Industrielle de la Peyrol B.P., France

  IcellatorR X        Semi-closed               Semi-automatic                    60--100 mL     No                                60             Tissue Genesis, Inc.\
                                                                                                                                                  Honolulu, Hawaii

  STEM-X              Closed                    Automatic                         20--800 cc     yes                               Not provided   Medikan Co., Ltd.\
                                                                                                                                                  Seoul, Korea

  SynGenX-1000        Closed                    Semiautomated                     250 mL         No                                Not provided   SynGen Inc.\
                                                                                                                                                  Sacramento. CA, USA

  Sepax-2             Semiclosed                Semiautomated                     300 g          No                                90             Biosafe Group SA\
                                                                                                                                                  Route Du Petit-Eysins 1 Eysins, Switzerland

  StromaCell          Closed                    Semiautomated                     Not provided   No                                Not provided   MicroAire Surgical Instruments, LLC\
                                                                                                                                                  Charlottesville, VA, USA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Preclinical studies and clinical trials of adipose stem cells (ASCs) applications.

  Diseases                        Pre-Clinical Studies   Clinical Trials                              Routine Treatment                                                 Effect of ASCs Therapy                                                           Autologous or Heterologous                      Ref.
  ------------------------------- ---------------------- -------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Knee osteoarthritis             Yes                    \-                                           Intra-articular injections                                        Improve pain, function and cartilage volume of the knee joint                    Autologous                                      \[[@B113-jcm-08-00917]\]
  \-                              Phase I                Intra-articular injection                    Decrease pain and improve WOMUA index                             Autologous                                                                       \[[@B114-jcm-08-00917]\]                        
  Degenerative disc disease       \-                     Yes                                          Injection                                                         Decrease low back pain                                                           Autologous                                      NCT02097862
  \-                              Yes                    Intradiscal implantation                     Improvement of flexion, pain ratings, VAS, PPI                    Stromal vascular fractions                                                       NCT02097862                                     
  Hip osteoarthritis              Yes                    \-                                           Intra-articular injection                                         Decrease pain and improve the function subscales                                 ASCs                                            \[[@B115-jcm-08-00917]\]
  \-                              Yes                    Percutaneous injections                      Regenerate cartilage-like tissue                                  ASCs                                                                             \[[@B116-jcm-08-00917]\]                        
  Cardiac disease                 Yes                    \-                                           Intracoronary reperfusion                                         Improve LVEF & reduce infarct area                                               Autologous ASCs                                 \[[@B117-jcm-08-00917]\]
  Heart failure                   \-                     Phase II                                     Intramyocardial injection                                                                                                                          Heterologous                                    NCT0267316
  Ischemic heart disease          \-                     Phase I/II                                   Intramyocardial injection                                         Increase myocardial perfusion                                                    Autologous                                      \[[@B118-jcm-08-00917]\]
  Ischemic cardiomyopathy         \-                     Phase I                                      Intravenous injection                                             Angiogenic effect                                                                Autologous                                      NCT00426868
  Critical limb ischemia          \-                     Phase I/II                                   Intramuscular injection                                           Angiogenic effect                                                                Autologous                                      NCT01211028
  Chronic myocardial ischemia     \-                     Phase I/II                                   Intramyocardial injection                                         Angiogenic effect                                                                Heterologous                                    NCT01556022
  Ischemic stroke                 \-                     Phase II                                     Intravenous injection                                             Angiogenic effect                                                                Heterologous                                    NCT01678534
  Stroke                          \-                     Phase II/III                                 Intravenous infusion                                              Angiogenic effect                                                                Heterologous                                    NCT02849613
  Amyotrophic lateral sclerosis   \-                     Phase I                                      Intravenous injection                                             Safety Improvement of ALS function, FVC                                          ASCs                                            NCT02492516
  Yes                             \-                     Transplantation                              Neuroprotective effects by increasing cytokine & growth factors   ASCs                                                                             \[[@B119-jcm-08-00917]\]                        
  Yes                             \-                     Intravenous injection                        Enhance the viability and motor activity                          Autologous                                                                       \[[@B98-jcm-08-00917],[@B99-jcm-08-00917]\]     
  Multiple system atrophy         \-                     Phase I                                      Intrathecal injections                                            Safety                                                                           Autologous                                      NCT02315027 \*
  \-                              Phase I/II             intrathecally via lumbar puncture            Safety at high dose                                               Autologous                                                                       \[[@B120-jcm-08-00917],[@B121-jcm-08-00917]\]   
  Spinal cord injury              \-                     Phase I/II                                   Intrathecal transplantation                                       Recover ASIA and sensory score                                                   Autologous                                      \[[@B104-jcm-08-00917]\]
  Rheumatoid arthritis            yes                    \-                                           Infusion                                                          Increase IL10, T-reg production                                                  Autologous                                      \[[@B122-jcm-08-00917]\]
                                  yes                    \-                                           Co-culture                                                        Inhibit inflammation                                                             Autologous                                      \[[@B123-jcm-08-00917],[@B124-jcm-08-00917]\]
  Type I diabetes mellitus        Yes                    \-                                           Intravenous transfusion                                           Improve glucose & insulin tolerance, increase insulin production                 Autologous                                      \[[@B125-jcm-08-00917]\]
  Type 2 Diabetes                 Yes                    \-                                           Intravenous injection                                             Increase insulin sensitivity, reduce inflammation and fat mass                   Autologous                                      \[[@B126-jcm-08-00917]\]
  Alzheimer's disease             Yes                    \-                                           Transplantation                                                   Enhance neurogenic activity, reduce oxidative stress                             Autologous                                      \[[@B127-jcm-08-00917]\]
  Yes                             \-                     Intravenously or intracerebrally injection   Increase cytokine IL10 & VEGF                                     Autologous                                                                       \[[@B128-jcm-08-00917]\]                        
  Parkinson's disease             Yes                    \-                                           Transplantation                                                   Neurogenesis increase cytokine secretion and brain-derived neurotrophic factor   Autologous                                      \[[@B129-jcm-08-00917]\]
  Yes                             \-                     Transplantation                              Improve motor function & neuroprotective effects                  Monolayer-cultured ASCs                                                          \[[@B130-jcm-08-00917]\]                        
  Traumatic brain injury          \-                     Phase I/II                                   Injection                                                         Safety Benefits                                                                  Autologous                                      NCT02959294 \*

LVEF---left ventricular injection fraction; VAS---Visual analog scale; PPI: present pain intensity; WOMUA index---Western Ontario and McMaster Universities Arthritis Index; ALS---amyotrophic lateral sclerosis; FVC---Forced Vital Capacity; ASIA---American Spinal Injury Association; \* Clinical trials are processing.
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